Diffusion of Botulinum Toxins

Matthew A. Brodsky 1*, David M. Swope 2 & David Grimes 3

1 Oregon Health & Science University, Portland, Oregon, United States of America, 2 Loma Linda University, Loma Linda, California, United States of America, 3 University of Ottawa, Ottawa, Canada

Abstract

Background: It is generally agreed that diffusion of botulinum toxin occurs, but the extent of the spread and its clinical importance are disputed. Many factors have been suggested to play a role but which have the most clinical relevance is a subject of much discussion.

Methods: This review discusses the variables affecting diffusion, including protein composition and molecular size as well as injection factors (e.g., volume, dose, injection method). It also discusses data on diffusion from comparative studies in animal models and human clinical trials that illustrate differences between the available botulinum toxin products (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and rimabotulinumtoxinB).

Results: Neither molecular weight nor the presence of complexing proteins appears to affect diffusion; however, injection volume, concentration, and dose all play roles and are modifiable. Both animal and human studies show that botulinum toxin products are not interchangeable, and that some products are associated with greater diffusion and higher rates of diffusion-related adverse events than others.

Discussion: Each of the botulinum toxins is a unique pharmacologic entity. A working knowledge of the different serotypes is essential to avoid unwanted diffusion-related adverse events. In addition, clinicians should be aware that the factors influencing diffusion may range from properties intrinsic to the drug to accurate muscle selection as well as dilution, volume, and dose injected.

Keywords: Botulinum toxin, diffusion, spread, injection technique

Citation: Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov 2012;2: http://tremorjournal.org/article/view/85

* To whom correspondence should be addressed. E-mail: brodskym@ohsu.edu

Editor: Elan D. Louis, Columbia University, United States of America

Received: December 3, 2011 Accepted: June 3, 2012 Published: August 6, 2012

Copyright: © 2012 Brodsky et al. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original author(s) and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: Funding for editorial support was provided by Merz Pharmaceuticals, LLC, Greensboro, NC.

Financial Disclosures: Dr. Brodsky has served as an advisor to Merz Pharma, Ipsen, Allergan, Inc., UCB, and Teva. Dr. Swope has received grant/research support from Allergan, Inc., Teva, Synosia/Bioite, and St Jude Medical Center; has served as an advisor for Allergan, Inc., Ipsen, Merz Pharma, and Teva; and has received fellowship support from Merz. He also is a member of the speakers’ bureau for Allergan, Inc. and is affiliated with its Injection Training Center. Dr. Grimes has served as an advisor to Merz Pharma, Allergan, Novartis, and Teva; he has received grant/research support from NIH, Michael J. Fox Foundation, CIHR, Parkinson Research Consortium, Impax Pharmaceuticals, Merz Pharma, Allergan and Schering-Plough.

Conflict of Interest: The authors report no conflict of interest.

Introduction

Botulinum toxin (BoNT) preparations act by binding presynaptically to high-affinity recognition sites on the cholinergic nerve terminals and decreasing the release of acetylcholine, causing a neuromuscular blocking effect. This inhibition of acetylcholine release leads to muscle weakness and the potential for the relief of undesirable muscle contraction, hence serving as an effective treatment for a wide range of muscle disorders including strabismus, blepharospasm, hemifacial spasm, cervical dystonia, and spasticity.

There are seven serologically distinct types of BoNT, designated A through G, which are antigenically and serologically distinct but structurally similar. All have similar neurotoxic properties resulting in flaccid muscle paralysis; however, only the A (onabotulinumtoxinA [ONAA], abobotulinumtoxinA [ABOA], and incobotulinumtoxinA [INCOA]) and B (rimabotulinumtoxinB [RIMAB]) forms have been approved for clinical use. Each botulinum product is purified and manufactured using proprietary processes, resulting in unique agents that differ in such features as molecular weight, uniformity of toxin complex size, protein content, and the presence of inactive ingredients, all of which can impact performance characteristics including potency, duration of effect, and adverse event (AE), and diffusion or migration profile.
The AEs associated with BoNT are generally of three types: those due to expected effects of the neurotoxin (e.g., excessive local muscle weakness), those due to diffusion of the neurotoxin to nearby, un.injected muscles, and those resulting from systemic distribution of the toxin. Diffusion of BoNT beyond the target muscle is of clinical concern because of the potential for local and systemic effects that result in muscle weakening away from the desired site. BoNT may diffuse across fascial planes to adjacent muscles or be spread hematogenously. At its extreme, the possible leakage of BoNT into the systemic circulation may manifest as clinical botulism, leading to respiratory failure and death.

**Methods**

In this review, published data on the variables affecting diffusion, including those pertaining to protein composition and molecular size of a given botulinum toxin and also factors such as injection volume and dose, and injection method (e.g., needle gauge used, speed of injection, and target muscle localization), are discussed. In addition, findings on diffusion from comparative studies in animal models and human clinical trials that illustrate differences between available, approved botulinum toxin products are elucidated. While this is not a systematic review, a prespecified protocol was followed for the literature search. Potentially relevant publications were obtained from a PubMed search conducted during October of 2010 by Linnéa Elliott and Maria Vinall of The Curry Rockefeller Group under the direction of the authors. The search focused on English language publications with the terms botulinum toxin, botulinum neurotoxin, and diffusion or migration. The results of this search were reviewed by the authors, who added additional publications they considered noteworthy but which were not identified by the search. Published abstracts from recent medical conferences in relevant fields were also searched, and pertinent abstracts from those were included in the review. The final choice of references was made by the authors.

**Results and discussion**

The diffusion characteristics of BoNT have been well studied in humans and animals, using a variety of techniques, including compound muscle action potentials (CMAPs) and motor-evoked potentials, histological determination of glycogen-depleted muscles, acetylcholine esterase staining, muscle fiber diameter variability, and quantitative electromyography (EMG) measures of muscle activity.

Evidence for diffusion comes from both animal and human studies. In a study using muscle biopsy to identify spread, Borodic et al. reported a diffusion gradient of BoNT/A over a distance of 30–45 mm from the point of injection into latissimus dorsi muscle of rabbits. The extent of denervation gradient or diffusion was dose dependent. Another study used neural cell adhesion molecule (N-CAM) staining to assess the diffusion of activity of equipotent doses of three BoNT/A formulations from the point of injection along the mouse hind limb. The results showed a similar time course of paralysis, and minimal but comparable diffusion in the anatomical area adjacent to the site of injection that decreased over time in a similar manner. Results of an electrophysiologic study in patients with blepharospasm and facial hemispasm treated for the first time with BoNT/A in the orbicularis oculi muscle showed a significant effect in untreated muscles with different peripheral innervation that could not be explained by axonal diffusion from the terminal nerve endings of the facial nerve and which the investigators concluded was related to local diffusion of the BoNT/A. A study that investigated whether the volume of solution used to inject equivalent units of botulinum exotoxin A affects the diffusion of toxin and areas of rhytid diminution in the treatment of dynamic forehead lines found that injection of botulinum exotoxin A in low concentration and higher volume resulted in greater diffusion and a larger affected area. The pattern of toxin spread was altered by muscular contraction in the injected sites.

Although most clinicians agree that diffusion of BoNT occurs, its extent and clinical importance has been disputed. In a study of patients receiving BoNT to treat hemifacial spasm, Lorenzano and colleagues assessed the nearby untreated muscles of patients, both clinically and neurophysiologically, and concluded that diffusion did not occur to any significant extent. This finding was echoed by Carl and colleagues, who reported that intramuscular injections of BoNT/A to the tibialis anterior muscle of mice exhibited only limited diffusion to adjacent muscles. In another animal study using radio-labeled BoNT and autoradiography, Tang-Liu and colleagues showed no detectable systemic effects or generalized botulinum neurotoxin toxicity, indicating that most of the toxin remained at the injection site.

Pickett et al. has suggested that the confusion regarding the extent and clinical relevance of diffusion among the different botulinum toxins can be attributed to incorrect extrapolations of information obtained from animal studies to clinical settings, the inappropriate testing of products with different dose ratios, the incorrect suggestion that products with larger complex molecular size migrate less, and, in some cases, poor study design.

Depending on the clinical indication for which it is used, diffusion of BoNT may be advantageous. Clinicians may capitalize on effects of diffusion when giving injections for palmar and axillary hyperhidrosis. When treating larger muscles with BoNT, most often seen in patients with spasticity, many investigators now recommend trying to increase the diffusion characteristics of the toxin by using high-dilution volumes.

**Variables that may affect diffusion**

It has been suggested that diffusion of BoNT is influenced by a number of factors such as dose, concentration, volume, rate of injection, needle size, distance of needle tip from the neuromuscular junction, number of injections, target muscle selection, the presence of muscular fascia, the presence of tissue damage at the injection site, muscle contraction following injection, and the protein composition and molecular size of the BoNT formulation. However, dose, concentration, and volume are probably the greatest contributors, in that the greater the dose, concentration, or volume, the greater the risk of diffusion (Table 1).
Diffusion of Botulinum Toxins

Brodsky MA, Swope DM, Grimes D

Preparations retaining the complexing proteins. 1,32 that INCOA has an 
hand weakness that was dose dependent (30% of participants in the 
study evaluating the safety and efficacy of two doses of ONAA (50 
units and 100 units) in the treatment of essential hand tremor reported 
the diffusion characteristics of the three products to 
be indistinguishable. In addition, in a long-term clinical study, 28 the 
diffusion profile of ONAA and INCOA (which is free of complexing 
proteins) did not differ, suggesting that the complexing proteins are 
neither necessary for BoNT’s therapeutic effect nor relevant for tissue 
diffusion. This is consistent with earlier findings that the 150-kDa 
neurotoxin molecule is released from the 900-kDa complex in less than 
a minute when exposed to physiological pH values. 29 There is also no 
difference between purified neurotoxin alone or toxin complex in 
terms of localization at the site of injection or subsequent migration 
into body tissues. 29 Other studies have also reported that smaller size 
or the absence of complexing plays no role in toxin diffusion, 30,31 and 
that INCOA has an in vivo diffusion profile comparable with that of 
preparations retaining the complexing proteins. 1,32

**Table 1. Factors Thought to Affect Diffusion**

| Factor                  | Does It Affect Diffusion? |
|-------------------------|---------------------------|
| Protein composition     | No                        |
| Molecular size          | No                        |
| Injection volume        | Yes                       |
| Injection dose          | Yes                       |
| Injection concentration | Yes                       |
| Injection method        | Maybe                     |

**Protein composition and molecular size**

Based on the principle that larger proteins diffuse more slowly 
through an identical aqueous medium than smaller proteins, Foster 
and colleagues 3 predicted that a BoNT of greater size or molecular 
weight would be less likely to diffuse outside the target tissue than those 
of smaller size. Thus, ONAA would be less likely to diffuse outside the 
target tissue than ABOA, RIMAB, or INCOA. However, Carli and 
colleagues 17 found the diffusion characteristics of the three products to 
be indistinguishable. In addition, in a long-term clinical study, 28 the 
diffusion profile of ONAA and INCOA (which is free of complexing 
proteins) did not differ, suggesting that the complexing proteins are 
neither necessary for BoNT’s therapeutic effect nor relevant for tissue 
diffusion. This is consistent with earlier findings that the 150-kDa 
neurotoxin molecule is released from the 900-kDa complex in less than 
a minute when exposed to physiological pH values. 29 There is also no 
difference between purified neurotoxin alone or toxin complex in 
terms of localization at the site of injection or subsequent migration 
into body tissues. 29 Other studies have also reported that smaller size 
or the absence of complexing plays no role in toxin diffusion, 30,31 and 
that INCOA has an in vivo diffusion profile comparable with that of 
preparations retaining the complexing proteins. 1,32

**Injection factors**

Diffusion of botulinum toxin may be dose dependent, and specific 
complications may be related to the choice of injection site. In a 
retrospective analysis of 26 patients with adult onset idiopathic 
spasmodic torticollis treated with BoNT/A for a mean of 1.1 years, 
Borodic et al. 14 noted that treatment with a median of 150 IU of 
ONAA resulted in a significantly (p=0.026) higher incidence of 
dysphagia than a median dose of 100 IU when the treatment was 
administered via the sternomastoid muscle but not when the posterior 
cervical muscle group was injected alone. When the investigators 
conducted a prospective study in the same patient population and 
limited the dose at the sternomastoid muscle to 100 IU, they noted a 
substantial decrease in the incidence of dysphagia. 14 Participants in a 
study evaluating the safety and efficacy of two doses of ONAA (50 
units and 100 units) in the treatment of essential hand tremor reported 
hand weakness that was dose dependent (30% of participants in the 
low-dose group and almost 70% in the high-dose group). 33 Injection 
site was not identified as a contributing factor in this study.

Injection volume has also been implicated as a factor in diffusion. In 
one study, a fivefold increase in volume resulted in an ~50% increase 
in affected area. 10 In another study, the diffusion gradient around the 
site of injection increased with the concentration of BoNT injected. 15 
At BoNT/A doses of 5–10 IU, a gradient of denervation occurred 
throughout the entire muscle with no apparent endpoint, suggesting 
that both the magnitude of denervation and the extent of the gradient 
are dose dependent. A possible consequence of greater volume leading 
to more diffusion into surrounding tissue may be diminution in 
duration and magnitude of effect. 10

It is most likely that both dose and volume are important 
determinants of the effects on the target muscle. Results of a dose-
-ranging, electroneurographic study investigating the dose equivalence, 
diffusion characteristics, and safety of ABOA and ONAA in 79 
volunteers showed significant and similar reductions in compound 
muscle action potential amplitude in the extensor digitorum brevis 2 
weeks after injection, with effects persisting to the 12-week time point. 
For both products, the reduction in amplitude increased with 
increasing doses and with increasing concentration. 27

Other injection-related factors that may influence diffusion but to a 
lesser extent include needle gauge and speed of injection, since too 
large a gauge needle and/or too fast an injection could lead to trauma 
to the target tissue with the result that toxin uptake in the target area is 
decreased, leaving more toxin to spread to adjacent areas. 26 
Spread can also be influenced by the distance between the tip of the 
needle and the neuromuscular junction (NMJ), with uptake being enhanced 
and spread reduced when the needle tip is close to a cluster of 
NMJs. 26,34 Rosales and colleagues 11 have suggested that muscle 
arborization (e.g., whether and how the individual muscle units are 
aranged in compartments) may also influence the spread of BoNT.

**Limiting diffusion**

Perhaps the most useful technique to limit diffusion is target muscle 
localization. Several techniques using EMG and endoscopic or 
imaging guidance are purported to increase the accuracy of targeting 
and thus reduce diffusion. Use of EMG, electrical stimulation (ES), or 
ultrasound guidance is employed in children for difficult-to-locate 
individual muscle groups. 26 EMG is also commonly used to confirm 
appropriate localization of the injection needle in specific muscles 
immediately before injection. Molloy and colleagues 35 examined the 
accuracy of muscle localization in patients with focal hand dystonia 
without EMG guidance and found that only 37% of needle placement 
Attempts reached the target muscles or muscle fascicles, demonstrating 
the need for EMG guidance for correct localization of desired muscles. 
In contrast, superficial, easily targeted muscles can be injected directly, 
without a need for special techniques. 36

Geenen and colleagues 37 studied 12 patients who received BoNT for 
 focal hand dystonia: eight patients under passive EMG guidance and 
four with ES. Although the limited study concluded that ES was at 
least as good as EMG monitoring, both injection techniques resulted in
weakness of non-targeted muscles. EMG guidance may be used with (active) or without (passive) ES. Passive EMG guidance can be used for the treatment of cervical and laryngeal dystonia, as well as strabismus. Active EMG guidance may be applied when treating writers’, musicians’, and typists’ cramps, spasticity, and other conditions where it is difficult to accurately target the muscle using voluntary contraction. EMG guidance may allow more precise injections and the identification and treatment of deep cervical muscles, and, indeed, the magnitude of improvement in cervical dystonia may be greater with EMG guidance.30

Ultrasound is a relatively convenient, painless, and less time-consuming procedure. Sconfienza and colleagues39 have reported that the use of ultrasound to guide needle positioning prior to injecting BoNT into the iliopsoas muscle in 10 patients with spinal lesions allowed for easy and exact needle placement. The use of ultrasound guidance has also been shown to produce results that are superior to manually guided injections in the treatment of sialorrhea in patients with Parkinson’s disease.30

**Comparative studies**

For each of the botulinum toxins the volume, dose, and accuracy of the toxin placement appear to have the most effect on the clinical outcome.

**Animal studies of diffusion**

The diffusion profiles of BoNT/A and BoNT/B products have been studied in numerous animal studies. In one study, equipotent doses of ONAA, ABOA, and INCOA caused a similar duration of paralysis with no difference in diffusion when injected into the tibialis anterior muscle of mice.17 However, in two other studies in which ONAA, ABOA, and RIMAB were injected into the gastrocnemius muscle of mice, ONAA displayed less diffusion than either ABOA or RIMAB.40,41 Different results were seen in a study that examined the effect of ONAA and RIMAB injected into the abductor pollicis brevis muscle of juvenile monkeys. In that study, the authors noted dose-dependent diffusion into both nearby and relatively remote muscles with ONAA but not RIMAB.11 The results from these studies confirm that some BoNT products are clearly not interchangeable and indicate that, at clinically effective doses, side-effect rates may be different.2

**Human clinical trials suggesting diffusion differences**

**ABOA versus ONAA.** In a crossover study in which 212 patients with blepharospasm were randomized to receive double-blind ONAA or ABOA (ONAA/ABOA ratio of 1:4 IU), ABOA was associated with a significantly (p<0.05) greater incidence of AEs than ONAA, specifically ptosis (three cases with ONAA versus 14 cases with ABOA; p<0.01). The authors hypothesized that the reason for the difference in AEs might be related to the diffusion profile of the two products.42 Results from a double-blind, randomized, three-period, crossover study involving 54 patients with cervical dystonia indicated that ABOA (ONAA/ABOA ratios of 1:3 and 1:4) is more efficient than ONAA for both impairment and pain in cervical dystonia; however, the number of AEs was higher with both ABOA treatments. The most frequent AE was dysphagia, found in 3%, 15.6%, and 17.3% (ONAA, ABOA 1:3, and 1:4, respectively) of the patients.43 The study results, reported by Ranoux and colleagues,44 differed from the only other study to compare the conversion factor between ONAA and ABOA units for the treatment of cervical dystonia44 in several respects. The earlier study was a parallel design, while the study by Ranoux and colleagues used a crossover design that allowed patients to serve as their own control, thus eliminating some of the individual differences that might contribute to an AE (e.g., a thin neck). In addition, in the study by Ranoux and colleagues, a standardized protocol for injections was used and the same volume was injected for each of the three treatments. In light of these controls, the authors suggested that the higher AE profile of ABOA may in some way be related to its efficacy and its greater tendency to diffuse within the tissues.43

In a review of clinical and preclinical studies evaluating the diffusion properties of ONAA, ABOA, and RIMAB, de Almeida and colleagues25 concluded that higher doses of ABOA are needed to achieve efficacy similar to ONAA and that these higher doses are associated with an increase in diffusion-related AEs. The authors suggested ONAA has the least potential for diffusion, followed by ABOA, then RIMAB. These results are in accord with prior studies noting a lack of dose equivalence between ONAA and ABOA. Sampaio and colleagues45 noted that 3–5 units of ABOA is required to achieve the same therapeutic or aesthetic effect as 1 unit of ONAA. Lowe and colleagues46 have suggested that when doses are titrated to provide similar efficacy, the result is a ratio of ED50 (e.g., effective dose for 50% of the population receiving drug) values of approximately 1:5 (ONAA:ABOA), noting that at this ratio ONAA has a lower risk of diffusion than ABOA.

**INCOA versus ONAA versus ABOA.** INCOA and ONAA have been found to have comparable efficacy and safety in large phase 3 clinical trials in blepharospasm47 and cervical dystonia.48 According to Frevert,49 the similar AE profiles seen in these studies are indicative of similar diffusion profiles. In a phase 1B study in 32 healthy volunteers, after injection of INCOA or ONAA into the extensor digitorum brevis muscle, CMAP analysis of two adjacent muscles (abductor hallucis and abductor digiti quinti) revealed no reduction of the muscle activity caused by diffusion after injection of either toxin.5

After intramuscular injection into the forehead, the diffusion profiles of INCOA and ONAA were not significantly different, while ABOA produced a significantly greater area of diffusion versus INCOA at comparable doses and identical volumes of injection.50,51

**RIMAB versus ONAA.** In a small study that investigated the diffusion of ONAA relative to RIMAB, RIMAB consistently produced a greater radius of toxin diffusion, as measured by the wrinkle reduction area, calculated using a digital micrometer on traced scanned images.9 Other, larger studies also suggest that RIMAB diffuses differently from the other botulinum toxins. In a multicenter, randomized, double-blind, parallel-arm study comparing ONAA and RIMAB for
treatment of cervical dystonia, both dysphagia and dry mouth were more frequent with RIMAB. Dysphagia was reported by 48% of subjects treated with RIMAB versus 19% treated with ONAA (p=0.0005); 80% of subjects treated with RIMAB reported dry mouth compared with 41% of ONAA-treated subjects (p=0.0001). In another report, mild (but not moderate/severe) dry mouth was also significantly (p=0.0005) more frequent with RIMAB than with ONAA. A systematic review and analysis of the published literature comparing rates of dysphagia and dry mouth showed clear differences with RIMAB. Among the 70 published articles included in the analysis, RIMAB had the highest number that reported an association with rates ranging from 3.2% to 90%. This would suggest that RIMAB has the highest local and systemic diffusion properties compared with the other toxins.

Conclusions

It is generally accepted that containment of BoNT diffusion is a desirable goal after injection. An accumulating body of evidence suggests that some of the botulinum agents have different diffusion characteristics. Meticulous placement of the toxin using correct dosing exactly targeted to the right muscle to produce a precise treatment effect offers the best chance of a good outcome. Techniques such as EMG guidance can also help to control the effects of diffusion by increasing the accuracy of the injection.

Although BoNT serotypes are structurally and functionally similar, specific differences in neuronal acceptor binding sites, intracellular enzymatic sites, and species sensitivities suggest that each serotype is its own unique pharmacologic entity, sometimes due to distinct purification and manufacturing procedures. Physicians must have a working knowledge of the different serotypes, different doses used for each formulation of each serotype, and the side-effect profile of each product in order to insure against diffusion-related AEs. One should also be aware that a number of factors influence comparative data on efficacy, diffusion, and spread. These factors may range from properties intrinsic to the drug to accurate muscle selection and to the dilution, volume, and doses injected. In particular, the results of the clinical trials must be considered within the context that there are still no data on the conversion rate among the various treatments. Thus, too high or too low concentrations may have been used in the individual studies, making it difficult to draw too firm a conclusion from any one trial.

Acknowledgment

Editorial support, consisting of substantive editing, copy editing, and styling of the authors’ draft, as well as assistance with literature searches, was provided by Linnée Elliott and Maria Vinall of The Curry Rockefeller Group, LLC, Tarrytown, NY.

References

1. Wohlforth K, Muller C, Sassin I, Comes G, Grafe S. Neuropsycho- logical double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Cln Neuropharmacol 2007;30:86–94, http://dx.doi.org/10.1097/01.WNF.0000240551.18821.50.

2. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin—from laboratory to bedside. Neurotox Res 2006;9:133–140, http://dx.doi.org/10.1007/BF03039391.

3. Tugnoli V, Eleopra R, Montecucco C, De Grandis D. The therapeutic use of botulinum toxin. Expert Opin Investig Drugs 1997;6:1383–1394, http://dx.doi.org/10.1517/13543784.6.10.1383.

4. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198, http://dx.doi.org/10.1136/jnnp.62.2.198.

5. Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90–93, http://dx.doi.org/10.1136/jnnp.67.1.90.

6. U.S. Food and Drug Administration. Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). 2009 [cited 2011 December 29]; Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164255.htm.

7. Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46:1158–1160, http://dx.doi.org/10.1212/WNL.46.4.1158.

8. Eleopra R, Tugnoli V, Quatrale R, Rossetto O, Montecucco C. Different types of botulinum toxin in humans. Mov Disord 2004;19(Suppl 8):S53–39, http://dx.doi.org/10.1002/mds.20010.

9. Flynn TC, Clark RE. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003;29:519–522, http://dx.doi.org/10.1097/01.6j.1524-4725.2003.29124.x.

10. Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004;140:1351–1354, http://dx.doi.org/10.1001/archderm.140.11.1351.

11. Rosales RL, Bigalke H, Dresser D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006;13 Suppl 1:2–10.

12. Yaraskavitch M, Leonard T, Herzog W. Botox produces functional weakness in non-injected muscles adjacent to the target muscle. J Biomech 2008;41:897–902, http://dx.doi.org/10.1016/j.jbiomech.2007.11.016.

13. Shaari CM, George E, Wu BL, Biller HF, Sanders I. Quantifying the spread of botulinum toxin through muscle fascia. Laryngoscope 1991;101:960–964, http://dx.doi.org/10.1288/00005537-199110900-00006.

14. Borodic GE, Joseph M, Fay L, Cozzolino D, Ferrante RJ. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990;12:392–399, http://dx.doi.org/10.1002/hed.2980091006.

15. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994;9:31–39, http://dx.doi.org/10.1002/mds.870901006.

16. Buchman AS, Comella CL, Stebbins GT, Tanner CM, Goetz CG. Quantitative electromyographic analysis of changes in muscle activity following...
botulinum toxin therapy for cervical dystonia. *Clin Neuropharmacol* 1993;16:205–210, http://dx.doi.org/10.1097/00002826-199306000-00003.

17. Carli L, Montecucco C, Rossetto O. Assay of diffusion of different botulinum neurotoxin type A formulations injected in the mouse leg. *Muscle Nerve* 2009;40:574–380, http://dx.doi.org/10.1002/mus.21343.

18. Lorenzano C, Baguato S, Gilio F, Fabbrini G, Berardelli A. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm. *Neurotox Res* 2006;9:141–144, http://dx.doi.org/10.1007/10363

19. Carli L, Montecucco C, Rossetto O. An histological assessment of diffusion of different botulinum neurotoxin type A formulations injected in the mice leg. *Toxicon* 2008;51[Suppl]:9.

20. Tang-Liu DD, Aoki KR, Dolly JO, et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. *Toxicon* 2003;42:461–469, http://dx.doi.org/10.1016/S0041-0101(03)00196-X.

21. Pickert A, Dodh S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. *J Cosmet Laser Ther* 2008;10:181–183, http://dx.doi.org/10.1080/14764170802994282.

22. Glogau RG. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. *CJA* 2002;18:319–197.

23. Goodman G. Diffusion and short-term efficacy of botulinum toxin A after the addition of hyaluronidase and its possible application for the treatment of axillary hyperhidrosis. *Dermatol Surg* 2003;29:533–538, http://dx.doi.org/10.1097/01.DDS.0000077438.08722.69.

24. Lim EC, Sct RC. Botulinum toxin: description of injection techniques and examination of controversies surrounding toxin diffusion. *Acta Neurol Scand* 2008;117:73–84.

25. de Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. *J Cosmet Laser Ther* 2007;9[Suppl 1]:17–22, http://dx.doi.org/10.1080/17429960701523794.

26. Kimnatt D. Botulinum Toxin A injections in children: technique and dosing issues. *Am J Phys Med Rehabil* 2004;83:S59–64, http://dx.doi.org/10.1097/01.PHM.0000141131.66648.E9.

27. Wohlfarth K, Schwantl I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. *J Neurol 2008;255:1932–1939.

28. Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. *Ear J Neurol* 2009;16[Suppl 2]:2–5.

29. Eisele KH, Taylor HV. Dissociation of the 900 kDa neurotoxin complex from c. botulinum under physiological conditions. *Toxicon* 2008;51[Suppl 1]:10.

30. Frevert J. Xeomin is free from complexing proteins. *Toxicon* 2009;54:697–701, http://dx.doi.org/10.1016/j.toxicon.2009.03.010.

31. Wohlfarth K, Sycha T, Ranous D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? *Can Med Res Pub* 2009;25:1573–1584, http://dx.doi.org/10.1185/030079909003028203.

32. Dressler D. Comparing Botox and Xeomin for axillary hyperhidrosis. *J Neural Transm* 2010;117:317–319, http://dx.doi.org/10.1007/s00702-010-0372-0.

33. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. *Neurology* 2001;56:1523–1528, http://dx.doi.org/10.1212/WNL.56.11.1523.

34. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. *J Neurol Neurosurg Psychiatry* 2009;80:380–385, http://dx.doi.org/10.1136/jnp.2008.159657.

35. Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. *Neurology* 2002;58:805–807, http://dx.doi.org/10.1212/01.WNL.0000568505.80650.8f.

36. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmotic torticollis: increased magnitude of benefit with electromyographic assistance. *Neurology* 1992;42:878–882, http://dx.doi.org/10.1212/WNL.42.4.878.

37. Geenen C, ConskeY, Ashly F. Localizing muscles for botulinum toxin treatment of focal hand dystonia. *CMA J Neurol* 1996;23:194–197.

38. Dogu O, Apaydin D, Sevim S, Talas DU, Araz M. Ultrasound-guided versus ‘blind’ intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson’s disease. *CJA Neurol Neurosurg Psychiatry* 2004;106:93–96, http://dx.doi.org/10.1016/j.cjep.2003.10.012.

39. Sconzfienza LM, Lacci F, Bruno A, Serafeni G. Ultrasound guidance can improve the outcome of botulinum toxin A injection. *Eu J Phys Rehabil Med* 2009;45:153.

40. Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. *Toxicon* 2001;39:1815–1820, http://dx.doi.org/10.1016/S0041-0101(01)00101-5.

41. Aoki KR. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. *Toxicon* 2002;40:923–928, http://dx.doi.org/10.1016/S0041-0101(02)00086-7.

42. Prussens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. *Graefe Arch Clin Exp Ophthalmol* 1997:235:197–199, http://dx.doi.org/10.1007/BF00941758.

43. Ranoux D, Gurd C, Fendrasi J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. *J Neurol Neurosurg Psychiatry* 2002;72:459–462.

44. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox treatment of cervical dystonia. *J Neurol Neurosurg Psychiatry* 1998;64:1–12, http://dx.doi.org/10.1136/jnnp.64.1.6.

45. Sampanio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. *Mol Disord* 2004;19[Suppl 8]:S129–125, http://dx.doi.org/10.1002/mds.20066.

46. Lowe P, Patauak R, Lowe N. Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. *J Am Acad Dermatol* 2006;55:975–980, http://dx.doi.org/10.1016/j.jaad.2006.07.006.

47. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharoaspasm. *J Neural Transm* 2006;113:303–312, http://dx.doi.org/10.1007/s00702-005-0323-3.
48. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949–1951, http://dx.doi.org/10.1212/01.WNL.0000163767.99354.C3.

49. Frevert J. Xeomin: an innovative new botulinum toxin type A. Eur J Neurol 2009;16(Suppl 2):11–13, http://dx.doi.org/10.1111/j.1468-1331.2009.02879.x.

50. Jost WH. Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT 201) in cervical dystonia and blepharospasm. Future Neurol 2007;2:483–493, http://dx.doi.org/10.2217/14796708.2.5.485.

51. Kerscher M, Maack M, Rether T, Krüger N. Diffusion characteristics of two different neurotoxins in patients with symmetric forehead lines. J Am Acad Dermatol 2007;56:AB199.

52. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65:1423–1429, http://dx.doi.org/10.1212/01.wnl.0000183055.81056.5c.

53. Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Disord 2008;23:510–517, http://dx.doi.org/10.1002/mds.21724.

54. Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther 2007;29:1325–1337, http://dx.doi.org/10.1016/j.clinthera.2007.07.020.

55. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 2000;55:S15–21.

56. Lee LH, Chang WN, Chang CS. The finding and evaluation of EMG-guided BOTOX injection in cervical dystonia. Acta Neurol Taiwan 2004;13:71–76.